Recent news on Biopharma Sentiment Index (BPSI)

The Biopharma Sentiment Index (BPSI) is a new survey-based product launched by Endpoints News to systematically track how industry participants feel about the biopharma sector.1

BPSI is based on a structured survey that Endpoints describes as using rigorous methodology, aiming to provide more reliable sentiment data than informal polls or anecdotal commentary.1

The index is intended to become a recurring feature that measures changes in sentiment among biopharma professionals over time, helping readers gauge industry confidence and outlook.1

Endpoints has integrated the Biopharma Sentiment Index into its subscription offering, using it both as an editorial product and as a way to enhance the value of paid access.1

The launch of BPSI reflects growing demand for data-driven insights into how investors, executives, and other stakeholders view funding conditions, deal-making, and drug development prospects in biopharma.1

Sources:

1. https://www.amediaoperator.com/news/survey-product-adds-to-endpoints-subscription-the-bottom-line/